Gain Therapeutics, Inc. Common Stock

GANXNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
1.26 USD
↘ 0.03 (2.33%)AT CLOSE (03:59 PM EDT)
1.32
↗ 0.06 (5.08%)
POST MARKET (AS OF 07:00 PM EDT)
Post Market
AS OF 07:00 PM EDT
1.32
↗ 0.06 (5.08%)
🟢Market: OPEN

Gain Therapeutics, Inc. Common Stock (GANX) is currently trading at $1.32. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, GANX trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Oct 23, 2026.

Open?$1.33
High?$1.34
Low?$1.22
Prev. Close?$1.29
Volume?641.0K
Avg. Volume?560.8K
VWAP?$1.28
Rel. Volume?1.14x
Bid / Ask
Bid?$1.25 × 100
Ask?$1.40 × 100
Spread?$0.15
Midpoint?$1.33
Valuation & Ratios
Market Cap?56.3M
Shares Out?N/A
Float?41.8M
Float %?95.8%
P/E Ratio?N/A
P/B Ratio?4.99
EPS?-$0.46
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Themes
Biotech - Drug Development›Neuroscience & CNSBiotech - Drug Development›Rare Disease Therapeutics
Employees
21
Market Cap
56.3M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.gaintherapeutics.com
Listed
2021-03-18
Address
4800 HAMPDEN LANE
BETHESDA, MD 20814
Phone: (301) 500-1556
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
35
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.18Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?7.31%Elevated
Short Interest?3.1M
Days to Cover?5.9
Free Float41.8M
Avg Daily Volume515.4K
Settlement Date2026-09-30
Financial Health
Current Ratio?4.36Strong
Quick Ratio?4.36Strong
Cash Ratio?3.81Strong
Debt/Equity?0.03Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
37
4.99FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-178.1%WEAK▾
ROA?
S&P
3
-130.4%WEAK▾
Cash Flow & Enterprise
FCF?$-18952455
Enterprise Value?$43.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist